AstraZeneca concluded fiscal year 2025 with total revenue reaching $58.7 billion, an 8% increase compared to the previous year. The primary catalyst for this performance was the oncology franchise, which generated $25.6 billion in sales, up 14% from 2024.
Leading the oncology portfolio, the lung cancer medication Tagrisso achieved $7.25 billion in annual sales. It was followed by the immunotherapy Imfinzi at $6.06 billion and Enhertu at $2.78 billion, the latter showing a remarkable 40% growth. Senior management anticipates these products will remain key revenue drivers in 2026, bolstered by recent and upcoming clinical indication expansions.
Based on solid commercial foundations and a promising pipeline—including an oral obesity candidate entering Phase III trials—AstraZeneca issued a steady outlook for 2026:
-
Total Revenue: Projected to increase by a mid-to-high single-digit percentage.
-
Core Earnings Per Share (EPS): Expected to grow by a low double-digit percentage.
Strategically, the company is aggressively expanding its global footprint with massive capital commitments: $50 billion to strengthen U.S. manufacturing and $15 billion for R&D expansion in China. The firm noted that its global reach and diversified revenue streams minimize concentration risks and ensure resilience against regional disruptions. Notably, having signed a pricing agreement with the U.S. administration in late 2025, AstraZeneca is exempt from specific tariffs for the next three years.